Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China

SAN FRANCISCO and SUZHOU, China, Oct. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... Biopharmaceuticals, Oncology, Regulatory Innovent Biologics, Eli Lilly, HALPRYZA, rituximab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news